Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has commenced a new pancreatic cancer trial, enrolling its first patient to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX. This trial, taking place in Australia and the US, aims to assess the safety, tolerability, and pharmacokinetics of narmafotinib, with dose-escalation expected to complete by Q1 2026. The trial’s initiation marks a significant milestone in the development of narmafotinib, which has shown promising results in preclinical studies and aims to improve survival rates in pancreatic cancer patients.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is particularly targeting fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 7,272,047
Technical Sentiment Signal: Buy
Current Market Cap: A$84.66M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.